Agilent filed a lawsuit against Twist nearly a year ago, alleging that Twist Cofounder and CEO Emily LeProust had stolen DNA oligonucleotide synthesis technology.
Through the deal, Ginkgo has picked up Gen9's manufacturing platform and suite of proprietary technologies, software, and informatics tools for DNA synthesis and assembly.
The company intends to use the proceeds of the round to advance its proprietary enzymatic DNA synthesis technology called EcoDNA.
The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.
The DNA foundries have been funded through an £18 million ($23.5 million) investment from the BBSRC and should all be fully operational by next year.
Gen9's arrangement with renewable products firm Amyris comes about two months after it launched an access program for its low-cost DNA synthesis services.
Seattle-based chemical manufacturer Arzeda will buy megabase quantities of synthetic DNA from Gen9 for use in developing new advanced molecules.
The Cambridge, Massachusetts-based DNA manufacturer is looking to max out its production capacity, which works best at high volume and throughput.
Agilent will offer its SureVector cloning kits through Eurofins and will supply components for cloning services performed by Eurofins.
The deal is the latest partnership to provide exposure for Cambridge, Massachusetts-based Gen9's BioFab gene synthesis platform.
Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.
The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.
The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.
In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.